Company Overview - Spartacus Acquisition Corp. II is a blank check company formed to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses [2] - The company intends to focus its search for initial business combination targets on technology, media, and telecommunications companies [2] - The leadership team includes Chairman Peter D. Aquino, CEO Igor Volshteyn, and CFO Mark Szynkowski, along with board members Christopher Downie, David Marshack, and Eric Edidin [2] Trading Information - Starting April 2, 2026, holders of units sold in the initial public offering can separately trade the Class A ordinary shares and warrants included in the units [1] - The Class A ordinary shares will trade under the symbol "TMTS" and the warrants under "TMTSW" on the Nasdaq Global Market [1] - Units that are not separated will continue to trade under the symbol "TMTSU" [1]

Core Insights - Global Crossing Airlines Group, Inc. (GlobalX) has commenced revenue operations for its first Airbus A319 aircraft, marking a significant milestone in its fleet expansion strategy for 2026 [2] - The company has received two additional A319 aircraft, which are expected to enter revenue service in Q2 2026, further enhancing its operational capacity [3] - GlobalX has also taken delivery of its first owned Airbus A320, transitioning towards a hybrid ownership model aimed at improving asset flexibility and reducing costs [4] Fleet Expansion - The first Airbus A319 (N316NV) has been successfully integrated into the company's Air Operator's Certificate and is now in revenue operation, reflecting the company's growth strategy [2] - Two additional A319 aircraft (N318NV and N319NV) are currently undergoing conformity preparations and are anticipated to begin revenue operations in the second quarter of 2026 [3] - The delivery of the owned Airbus A320 (MSN 2840) is a continuation of the company's strategic shift from an exclusively leased fleet to a hybrid ownership model, expected to be operational in Q2 2026 [4] Management Commentary - The President and CFO of GlobalX, Ryan Goepel, emphasized that the pace of fleet delivery and integration showcases the strength of the team and partnerships, indicating a robust revenue generation model [5] Investor Engagement - GlobalX management will participate in three investor conferences in Spring 2026, providing opportunities for engagement with investors [6][9]

Core Insights - nCino, Inc. has appointed Keith Kettell as Chief Revenue Officer, effective April 1, 2026, to lead the company's revenue organization during its next growth phase [1][3] Company Overview - nCino is a leading provider of intelligent banking solutions, aiming to help financial institutions digitize and enhance business processes for improved efficiency and customer experience [4] - The company serves over 2,700 customers globally, including community banks, credit unions, independent mortgage banks, and major financial entities [4] Leadership Background - Keith Kettell has over 20 years of experience in building go-to-market organizations in technology and financial services [2] - His previous roles include significant contributions at Salesforce, where he developed the financial services go-to-market strategy, and as Chief Revenue Officer at Alloy, focusing on sales and marketing efficiency [2][3] Strategic Vision - Kettell emphasizes the need for financial institutions to transform operations amid pressures and the rapid evolution of AI technology [3] - nCino is positioned to capitalize on the transformation within the financial services sector, with a strong product offering and market position [3]

Core Insights - OrthoPediatrics Corp. is focused on advancing pediatric orthopedics and will participate in the 25th Annual Needham Virtual Healthcare Conference [1][2] Company Overview - Founded in 2006, OrthoPediatrics specializes in pediatric orthopedics, offering over 85 products across three major categories: trauma and deformity, scoliosis, and sports medicine/other procedures [3] - The company operates a global sales organization dedicated to pediatric orthopedics, distributing products in the United States and over 75 countries internationally [3]

Core Insights - Rekor Systems, Inc. reported a significant reduction in adjusted EBITDA loss by approximately 38% due to year-over-year revenue growth and improved gross margins, indicating operational efficiency and strategic repositioning [1][7][11]. Financial Highlights - Revenue for the year ended December 31, 2025, increased by approximately 5% year-over-year, reaching $48,450,000 compared to $46,028,000 in 2024 [8][24]. - Gross margins expanded to 56%, up from 49% in 2024, driven by a focus on higher-value, recurring revenue streams [7][10]. - Adjusted gross profit increased by 19%, amounting to $27,071,000 compared to $22,684,000 in the previous year [8][10]. - The company achieved positive operating cash flow in Q4 2025, marking its first quarter of cash inflow from operations [7]. Operational Highlights - The company reduced non-recurring engineering spending and aligned its cost structure with current revenue scale, enhancing operational performance [3][4]. - Integration of STS and ATD subsidiaries led to the elimination of legacy complexity and unlocked operational synergies [7]. - On-shoring of Rekor Command engineering and product operations to the U.S. improved customer coordination and service delivery [7]. Strategic Highlights - Rekor made significant progress in positioning itself for scalable growth, transitioning to a product-first portfolio with fully commercialized products such as Rekor Scout, Rekor Discover, and Rekor Command [5][7]. - The company secured a landmark patent for "Incident-Based" data retention, enhancing its product offerings while ensuring privacy [7]. - Plans to launch Rekor Labs, a new subsidiary focused on patented products for identifying synthetically created and modified media, were announced [7].

Core Insights - Roluperidone is the only late-stage drug candidate for treating negative symptoms of schizophrenia, with consistent positive results from prior pivotal trials [1][4] - The first patient has been screened for a global Phase 3 clinical trial evaluating roluperidone as monotherapy for negative symptoms of schizophrenia, which currently has no FDA-approved treatments [2][4] Phase 3 Trial Overview - The Phase 3 trial will enroll approximately 380 patients across 40 clinical sites worldwide, including the US and Europe, following discussions with the FDA on trial design [3][5] - The trial aims to confirm the efficacy of roluperidone on primary negative symptoms at 12 weeks compared to placebo and evaluate long-term relapse of positive symptoms over an additional 40 weeks [5][8] Trial Design and Objectives - The trial consists of two phases: Phase A (12 weeks) focuses on the primary endpoint of change in the Marder Negative Symptoms Factor Score, while Phase B (40 weeks) compares relapse rates with commonly prescribed antipsychotic medications [6][7][8] - The design includes standardized assessments and caregiver engagement to minimize variability and maximize sensitivity to treatment effects [6] Expected Outcomes - Topline data from the 12-week Phase A portion is anticipated in the second half of 2027, which will provide insights into the primary efficacy endpoint [6][7]

Core Viewpoint - Dave & Buster's Entertainment, Inc. reported a decline in financial performance for the fourth quarter and fiscal year ended February 3, 2026, with a focus on improving operations through strategic initiatives and a back-to-basics approach [1][6][7]. Financial Summary - Revenue for the fourth quarter was $529.6 million, a decrease of 0.9% from the same period in fiscal 2024 [9]. - Comparable store sales fell by 3.3% year-over-year, with an estimated decrease of 1.5% when excluding the impact of Winter Storm Fern [9]. - The net loss for the fourth quarter was $39.8 million, or $1.15 per diluted share, compared to a net income of $9.3 million, or $0.24 per diluted share in the fourth quarter of fiscal 2024 [9]. - Adjusted EBITDA for the fourth quarter was $111.4 million, down from $127.2 million in the same quarter of fiscal 2024 [9]. Annual Performance - Total revenue for fiscal 2025 was $2.1 billion, a decrease of 1.4% from fiscal 2024 [9]. - Comparable store sales decreased by 5.0% compared to fiscal 2024 [9]. - The net loss for fiscal 2025 was $48.7 million, or $1.40 per share, compared to a net income of $58.3 million, or $1.46 per diluted share in fiscal 2024 [9]. - Adjusted EBITDA for fiscal 2025 was $436.6 million, down from $506.2 million in fiscal 2024 [9]. Operational Developments - The company opened two new stores in the fourth quarter, totaling 11 new stores for fiscal 2025 [9]. - A total of 16 Dave & Buster's stores were remodeled in fiscal 2025, bringing the total to 51 since the remodel program began in the second half of fiscal 2023 [9]. - The company ended the fourth quarter with $482.9 million in liquidity, including $16.6 million in cash and $466.3 million available under its revolving credit facility [9]. Strategic Initiatives - The CEO emphasized a back-to-basics strategy aimed at improving operating results through enhanced food and beverage offerings, disciplined marketing, and a refined value proposition [6][7]. - Plans for 2026 include sharpening marketing efforts, refining pricing and menu architecture, launching new games, and implementing a remodel program [7]. - The company expects to deliver an increase in same-store sales, revenue, and Adjusted EBITDA, along with generating over $100 million in free cash flow during fiscal 2026 [7].

Core Insights - Nano Dimension Ltd. reported a full-year revenue of $102.4 million for 2025, marking a 77.3% increase compared to the previous year [1] - The company is focused on driving cost reductions and operational discipline, with significant progress made in 2025 [6][8] - Financial guidance for 2026 has been issued, projecting revenue between $130 million and $140 million [10] Financial Performance - For the fourth quarter of 2025, revenue reached $35.3 million, a 142.4% increase from $14.6 million year-over-year [7] - Gross margin for the full year was 33.5%, down from 43.1% year-over-year, while adjusted gross margin improved to 46.9% from 45.4% [7] - The adjusted EBITDA loss for 2025 was $53.2 million, an improvement from a loss of $63.6 million in the previous year [7] Cost Management - Non-GAAP operating expenses decreased to $27.3 million in Q4 2025, a reduction of over 16% from a baseline of approximately $32.5 million [6] - The company is implementing further cost reduction initiatives to enhance operational performance and improve operating leverage [8] Strategic Developments - A strategic alternatives review is underway, with expectations to announce a clear path forward in Q2 2026 [1][13] - The company has begun reporting as a U.S. domestic issuer effective January 1, 2026, aligning its governance with U.S. market standards [13] Shareholder Value - During 2025, the company repurchased approximately 10.9 million shares for about $19.2 million under its existing $150 million authorization [13] - The board is evaluating capital deployment priorities amid the ongoing strategic alternatives review [13]

Core Viewpoint - Datacentrex, Inc. has successfully closed a public offering, raising gross proceeds of $20.17 million through the sale of 4,510,000 shares of common stock and 5,757,000 pre-funded warrants at a price of $2.00 per share [1][2]. Group 1: Offering Details - The public offering included 4,510,000 shares of common stock and 5,757,000 pre-funded warrants, resulting in gross proceeds of $20.17 million before expenses [1]. - The net proceeds from the offering will be utilized for working capital and general corporate purposes [2]. - Dominari Securities LLC served as the exclusive placement agent for the offering [2]. Group 2: Regulatory Information - The offering was conducted under an effective shelf registration statement on Form S-3, initially filed with the SEC on May 2, 2025, and declared effective on May 30, 2025 [2]. - A preliminary prospectus supplement was filed with the SEC on March 26, 2026, and a final prospectus supplement was filed on March 30, 2026, both available on the SEC's website [3]. Group 3: Company Overview - Datacentrex is a digital infrastructure and capital deployment company that operates Scrypt compute assets and evaluates strategic transactions across asset-backed operating businesses [5]. - The company's operations focus on Scrypt-based proof-of-work compute deployed through third-party colocation facilities, monetizing this compute primarily through hashrate marketplace mechanisms [5].

Core Viewpoint - InspireMD, Inc. is set to present at the 25th Annual Needham Virtual Healthcare Conference, highlighting its focus on the CGuard Prime carotid stent system aimed at stroke prevention [1]. Company Overview - InspireMD, Inc. utilizes proprietary MicroNet™ mesh technology to establish its products as the industry standard for carotid stenting, aiming for excellent acute results and long-term stroke-free outcomes [2]. - The company's common stock is traded on Nasdaq under the ticker symbol NSPR, and it regularly updates important information for investors on its website [2].